Cancer drug development is a complex and costly process.
Selinexor is a drug that received accelerated approval as a new treatment for relapsed or refractory diffuse-large B-cell lymphoma and multiple myeloma.
Despite initially showing promise in treating these conditions, it has shown high-grade toxicity in clinical trials.
Hence, an analysis is needed to assess the clinical trial portfolio of selinexor.
